Feed aggregator

The Many Ways Biopharma Can Use Artificial Intelligence, Including Generative AI

Biospace news - Wed, 05/15/2024 - 02:00
The Many Ways Biopharma Can Use Artificial Intelligence, Including Generative AI 5/15/2024

Bayer Layoffs, a Big Alzheimer’s Deal, and ASGCT Wrap

Biospace news - Wed, 05/15/2024 - 02:00
Bayer Layoffs, a Big Alzheimer’s Deal, and ASGCT Wrap 5/15/2024

Novel inhibitor insights offer pathway to preventing PXR-associated drug resistance

World Pharma News - Tue, 05/14/2024 - 10:00
Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs. This causes a significant drop in the effectiveness of chemotherapy, antivirals and other pharmaceuticals. Blocking the PXR activity is notoriously difficult, as many drugs that bind the protein, whether intentionally or unintentionally, activate it. Scientists at St. Jude Children’s Research Hospital have leveraged chemical and structural studies in the design of PXR inhibitors to better understand this process.

Bayer Cuts 1,500 Jobs and Lowers 2024 Earnings Guidance as Q1 Sales Dip

Biospace news - Tue, 05/14/2024 - 02:00
Bayer Cuts 1,500 Jobs and Lowers 2024 Earnings Guidance as Q1 Sales Dip 5/14/2024

Novo Nordisk’s Wegovy Sustains Weight Loss for Four Years in Two Studies

Biospace news - Tue, 05/14/2024 - 02:00
Novo Nordisk’s Wegovy Sustains Weight Loss for Four Years in Two Studies 5/14/2024

Cytokinetics’ Phase III Data Sets Up Cardiomyopathy Challenge to BMS

Biospace news - Tue, 05/14/2024 - 02:00
Cytokinetics’ Phase III Data Sets Up Cardiomyopathy Challenge to BMS 5/14/2024

AbbVie, Gilgamesh Sign Potential $2B Deal to Develop Next-Gen Psychedelics for Psychiatric Disorders

Biospace news - Tue, 05/14/2024 - 02:00
AbbVie, Gilgamesh Sign Potential $2B Deal to Develop Next-Gen Psychedelics for Psychiatric Disorders 5/14/2024

Herpes cure with gene editing makes progress in laboratory studies

World Pharma News - Mon, 05/13/2024 - 10:00
Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an infected individual, which suggests that the therapy would also reduce the spread of the virus.

"Herpes is very sneaky. It hides out among nerve cells and then reawakens and causes painful skin blisters," said Keith Jerome, MD, PhD, professor in the Vaccine and Infectious Disease Division at Fred Hutch.

Sanofi, Pfizer, AstraZeneca Pledge Nearly $2.16B in Total Investments in France

Biospace news - Mon, 05/13/2024 - 02:00
Sanofi, Pfizer, AstraZeneca Pledge Nearly $2.16B in Total Investments in France 5/13/2024

Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts

Biospace news - Mon, 05/13/2024 - 02:00
Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts 5/13/2024

Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy

Biospace news - Mon, 05/13/2024 - 02:00
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy 5/13/2024

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs

Biospace news - Mon, 05/13/2024 - 02:00
BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs 5/13/2024

Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy?

Biospace news - Mon, 05/13/2024 - 02:00
Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy? 5/13/2024

Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market

Biospace news - Mon, 05/13/2024 - 02:00
Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market 5/13/2024

FDA Action Alert: Dynavax, Ascendis and BMS

Biospace news - Mon, 05/13/2024 - 02:00
FDA Action Alert: Dynavax, Ascendis and BMS 5/13/2024

Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study

Biospace news - Mon, 05/13/2024 - 02:00
Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study 5/13/2024

Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials

Biospace news - Mon, 05/13/2024 - 02:00
Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials 5/13/2024

Scientists pinpoint new vaccine "booster" that promotes potent anti-tumour immunity

World Pharma News - Fri, 05/10/2024 - 10:00
Scientists from Trinity College Dublin have made an important breakthrough that offers promise for developing new immune therapies for cancer. They have discovered that a vaccine adjuvant - or "booster" - called C100 promotes potent anti-tumour immunity when it is injected directly into tumours in an animal model.

The scientists found that C100, derived from chitin - one of the most common building materials in nature, and which gives strength to the exoskeletons of crustaceans, insects, and the cell walls of fungi - is highly effective at stimulating a key sensing and signalling molecule which regulates anti-tumour immune responses.

New treatment could reverse hair loss caused by an autoimmune skin disease

World Pharma News - Thu, 05/09/2024 - 10:00
Researchers at MIT, Brigham and Women's Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and affects people of all ages, including children.

For most patients with this type of hair loss, there is no effective treatment. The team developed a microneedle patch that can be painlessly applied to the scalp and releases drugs that help to rebalance the immune response at the site, halting the autoimmune attack.

AI predicts tumor-killing cells with high accuracy

World Pharma News - Wed, 05/08/2024 - 10:00
Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies.

Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be applied to personalized cancer treatments that tailor therapy to the unique cellular makeup of each patient's tumors.